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P A R A L L E L O P PO S E D ED I T O R I A L
Three discipline collaborative radiation therapy (3DCRT)
special debate: Equipment development is stifling innovation
in radiation oncology
1 | THREE DISCIPLINE COLLABORATIVE
RADIATION THERAPY (3DCRT) DEBATE
Radiation Oncology is a highly multidisciplinary medical specialty,
drawing significantly from three scientific disciplines — medicine,
physics, and biology. As a result, discussion of controversies or
changes in practice within radiation oncology involves input from all
three disciplines. For this reason, significant effort has been
expended recently to foster collaborative multidisciplinary research
in radiation oncology, with substantial demonstrated benefit1,2. In
light of these results, we endeavor here to adopt this “team‐science”
approach to the traditional debates featured in this journal. This arti-
cle represents the fifth in a series of special debates entitled “three
discipline collaborative radiation therapy (3DCRT)” in which each
debate team will include a radiation oncologist, medical physicist,
and radiobiologist. We hope that this format will not only be engag-
ing for the readership but will also foster further collaboration in the
science and clinical practice of radiation oncology.
2 | INTRODUCTION
The field of radiation oncology has recently experienced a period of
remarkable transformation of our technical capabilities. These techni-
cal and computational advancements have resulted in a tremendous
improvement in our ability to precisely and accurately deliver radiation
dose. However, this increased emphasis on technical capabilities may
be inadvertently diverting attention and funding from scientific devel-
opments in other areas, even at a time when exciting new advances
are occurring in cancer biology. Much of our recent technical develop-
ment has been promoted and subsidized by the manufacturers of
radiation oncology equipment. The question now becomes “who will
encourage and subsidize the research needed to bring our recent bio-
logical advances to clinical fruition?” In a recent commentary which
inspired this debate, Brown and Adler suggest that we “…are in a
golden age of radiation and cancer biology” and that “…the industry's
current focus on equipment development alone is undermining signifi-
cant potential clinical advances in radiation oncology.”3 This is the
subject of this month's 3DCRT debate.
Arguing for the proposition will be Drs. Leonard Kim, Stephanie
Markovina, and Samantha Van Nest. Dr. Leonard Kim has worked on
defining microscopic disease target volumes for breast cancer radio-
therapy at William Beaumont Hospital and Rutgers Cancer Institute
of New Jersey. He is currently Chief Medical Physicist at the MD
Anderson Cancer Center at Cooper.
Dr. Stephanie Markovina is interested in improving therapeutic
response to radiation in cervical cancer and other solid tumors by
better understanding molecular mechanisms of radiation induced
tumor cell death and survival. She is an Assistant Professor of Radia-
tion Oncology and Cancer Biology at Washington University in St
Louis where she specializes primarily in the treatment of patients
with gynecologic cancers.
Dr. Samantha Van Nest has worked to establish spectroscopic
techniques for the personalization of radiation therapy. She is cur-
rently a Postdoctoral Associate at Weill Cornell Medicine in New
York, where her research investigates the effects of radiation on
tumor immunity, with a particular focus on improving our under-
standing of the abscopal effect.
Arguing against the proposition will be Drs. Subarna Eisaman,
Lakshmi Santanam, and Julie Sullivan. Dr. Subarna Hamid Eisaman is
the clinical director and assistant professor at the University of Pitts-
burgh Medical Center (UPMC) Hillman Cancer Center Department of
Radiation Oncology at the J. Murtha Pavilion in Johnstown, Pennsyl-
vania. She serves as co‐chair of the Radiation Oncology Lung and
Lymphoma Via Oncology Pathways Physician Advisory Committee.
Her clinical practice includes treatment of breast, GYN, lung, CNS,
head and neck, skin and musculoskeletal malignancies.
Dr. Lakshmi Santanam is an attending medical physicist at
Memorial Sloan Kettering Cancer Center. Her primary interests
include motion management and patient safety. She currently serves
as vice chair for the AAPM Working Group on RO‐ILS and the Task
Group on the Management of Respiratory Motion in Radiation
Oncology.
Dr. Julie Sullivan is a biologist at the U.S. Food and Drug Admin-
istration's (FDA) Center for Devices and Radiological Health. Her sci-
entific interests include the use of radiation‐emitting medical devices
in clinical trials and the medical planning for and response to radio-
logical and nuclear incidents.
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3 | OPENING STATEMENTS
3.A | Leonard Kim, MS, AMusD; Stephanie
Markovina, MD, PhD; Samantha Van Nest, PhD
Radiation oncology is a science, and good science balances theory and
experiment: the questions we seek to answer and the means to
answer them. Without balance, progress and innovation can stall. For
example, a “crisis” in high‐energy particle physics has been in the news
lately, in which current technology does not or cannot validate the-
ory.4 In radiation oncology, we have arguably the opposite imbalance.
Equipment development is giving us answers to questions that per-
haps should not be our top priority, questions such as “how good is
my dose delivery now?” Certainly, continued improvement in delivery
accuracy have contributed to the reduction in planning target volume
(PTV) margins. But the clinical impact of further improvements to
something that is already at submillimeter levels in some cases is cer-
tainly questionable given that, for example, the most sizable and
uncertain margin today is probably the clinical target volume (CTV),
which must be attacked through a better understanding of the biology
underlying each cancer scenario rather than setup accuracy.
More insidiously, equipment development can influence the
questions researchers choose to ask. This influence can take several
forms. One is availability: though protons have been used clinically
for decades, does it surprise anyone that there have been as many
publications on proton radiotherapy in the past 5 years as in the
15 years previous to that? Characterizing newly available technology
and its usage, even when it is not truly novel, is a comparatively
easy path to the research productivity required for professional
advancement in our field. It is a path additionally laden with incen-
tives in the form of financial support from vendors. Although data
are not generally available to the public, funding for research and
development by these entities presumably favor efforts likely to gen-
erate new sources of revenue through either increased technical
complexity, additional procedures, or expanded clinical indications.
Given the continued cost to companies to develop and clinics to
purchase up‐to‐date but mainstream technology (linear accelerators,
high dose rate (HDR) remote afterloaders, imagers, etc.), develop-
ment of existing equipment is likely the primary focus of research
and development funding.
To be fair, many have found inspiration in asking, “what can I do
with this new capability?” But it might be better if we did not let the
tail of equipment development wag the dog of radiation oncology to
the extent that it does. Forget capability for a moment. What are
the questions we want to be answered, particularly clinical and bio-
logical questions, so that we can really innovate our field? Improved
understanding of the biological effects of radiation as well as the
biological factors that affect radiation response are needed. Explor-
ing these fundamental processes could lead to the development of
innovative new technologies that use radiation in ways we currently
are not.
For example, a meta‐analysis of radiation therapy (RT) techniques
for the treatment of medically inoperable early‐stage non‐small cell
lung cancer (NSCLC) reported a 2‐year overall survival estimate of
53% for conventional RT.5 Improvements in radiation dose delivery
and hypofractionation using stereotactic body radiation therapy
(SBRT) improved 2‐year survival to 70%.6 Despite these improve-
ments, distant disease recurrence develops in approximately 20% of
patients following SBRT.6,7 This is an example where clinical evi-
dence suggests that despite technology‐based improvements in
treatment delivery, there is an unmet need to address the systemic
reduction of disease. Another example is the treatment of cervical
cancer, where improved local control through advances in radiother-
apy delivery such as image guidance for brachytherapy have not
translated into improved cancer‐specific mortality, which for cervical
cancer has not improved over the last several decades.8 Unpre-
dictable systemic effects of radiation have not been adequately char-
acterized or addressed. Both pro‐metastatic behavior as well as
systemic reduction (known as the abscopal effect) have been
observed in tumors treated with radiation.9–17 Radiation therapy and
the technological drive toward conformality capitalize on the well‐
characterized cytotoxic effect of radiation, but we need a better
understanding of the dynamics between radiation and the complex
biological system we are treating. This understanding in turn could
lead to significant advances and even paradigm shifts in the way
radiation is used to treat cancer. The use of immune modulation in
combination with radiation therapy,18–21 the characterization of
microscopic disease that compose the CTV,22 the effects of tumor
microenvironment,23 and genomic heterogeneity leading to potential
differences in radioresistance24,25 are all other important areas of
research that have the potential to drastically change radiation
oncology. By investing research efforts into a more fundamental
understanding of the biological basis of our targets, we can poten-
tially improve patient outcomes and better utilize the equipment that
is already developed.
In the US, government funding accounts for much of the funding
for radiation oncology research. While there appears to be an
emphasis on cancer biology amongst National Institutes of Health
(NIH) funded grants, the total funding for a treatment modality (radi-
ation) which is applied to two‐thirds of all cancer patients is a mere
1.6% of NIH funding for cancer research.26 Additionally, radiation
oncology vendors should be motivated to invest in better under-
standing of cancer biology and specifically radiation biology, particu-
larly in the setting of newer techniques such as SBRT and the
implementation of increasing numbers of targeted agents. Not only
could the efficacy of traditional radiation therapy be maximized with
this approach, but novel indications for radiation as discussed above
could greatly expand the use of radiotherapy and thus existing radio-
therapy equipment. New inquiry should also include the effect of
different radiation modalities on “normal tissues” affected by other
pathologies such as seizure disorder, cardiovascular disease, and car-
diac conductivity disorders to name only a few.
In conclusion, the field of radiation oncology must prioritize over-
all improvement in the quality of life and effectiveness of our thera-
pies as motivation for innovation and not be swayed by industry or
economic pressures. Equipment development has no doubt allowed
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some of the biggest improvements in radiation therapy over the last
several decades. However, this return is increasingly diminishing, and
now is not the time to be continually tweaking already accurate,
excellent equipment. Now is the time to devote resources and effort
to answering pressing cancer and radiation biology questions. Any
new equipment development should answer to these questions
alone.
3.B | Subarna Eisaman, MD, PhD; Lakshmi
Santanam, PhD; Julie Sullivan, PhD
Radiation oncology is unique and effective because it is a fusion of
technology and biology with equipment development as an integral
part of innovation. Often, equipment development pushes the
boundaries of the field heralding a new era of novel therapies. For
example, equipment development for delivery of intensity‐modulated
radiation therapy (IMRT) supplanted older treatment techniques in
many cancer sites, especially head and neck (H&N).27 Among many
others, Wang et al.28 showed that better contralateral salivary gland
sparing with IMRT improved patient saliva output and grade of
xerostomia post treatment, a critical improvement in the patient's
quality of life.
Furthermore, technological advances in image guidance and
treatment delivery techniques paved the path for SBRT. SBRT pro-
vided an innovative way to target recurrent or second primaries
within previously irradiated H&N cancers.29 A multi‐institutional
study showed feasibility of loco‐regional control with SBRT in 197
H&N patients who had received previous median radiation dose of
70 Gy.30 Again, a huge step toward innovative solution for a patient
population with extremely limited options. As Aznar et al.31 point
out these equipment advances have paved the path to the first NRG
Oncology Group initiated phase 1 clinical trial of SBRT for the treat-
ment of multiple metastases in multiple organ sites (BR001;
NCT02206334).32
Moving beyond 2 Gy fractions is unlikely to have occurred with-
out knowing that treatment with higher doses could be done safely
and effectively. The wide spread application of SBRT has in turn trig-
gered innovative variations in radiobiological models. Universal sur-
vival curve (USC), published in 2008,33 compares different
fractionations of both conventionally fractionated radiotherapy and
SBRT. Mehta et al. suggest based on their clinical data for early
stage NSCLC, the high rate of local tumor control achieved by SBRT
can be fully explained by the much higher biological effective
dose.34
With the development of high definition multi‐leaf collimators
(MLCs), sophisticated treatment delivery systems, and image guid-
ance, it is possible to precisely deliver very high doses of radiation.
New ancillary systems like surface tracking, electromagnetic
transponder tracking in addition to existing motion management sys-
tems paves the way to reduce tumor margins and potentially reduce
normal tissue toxicity. The latest in the innovation chain are mag-
netic resonance (MR) guided radiotherapy systems that allow real‐
time visualization of the tumor without any extra imaging dose to
patients. This in turn helps overcome the common challenge of spar-
ing uninvolved liver and nearby organs at risk (OAR) (e.g., kidney and
bowel). Henke et al. 35 reported the first clinical outcomes of 26
patients treated for various liver malignancies showing MR‐guided
SBRT is well tolerated and can provide excellent local control. This is
being further fine‐tuned using daily online adaptive re‐optimization
since significant inter‐fractional changes in OAR positions were
observed despite breath‐hold stereotactic ablative radiation therapy
delivery under MR‐guidance. For example, in 17 patients treated for
adrenal metastases with total 84 fractions, online re‐optimization
improved target coverage in 63% of fractions and reduced the num-
ber of fractions not meeting the V95% objective for gross tumor vol-
ume (GTV) and PTV.36
Outside of the external beam systems, equipment development
has led to physical methods for pushing sensitive tissues away from
tumors using rectal spacers intended to create a rectal‐prostate
space, and HDR applicators specific to patient anatomy leading to a
more conformal tumor dose. A phase III trial studying 222 men
receiving 79.2 Gy in 1.8‐Gy fractions to the prostate demonstrated
significant reduction in 3‐year incidence in rectal toxicity in favor of
a hydrogel spacer (grade ≥ 2 toxicity 5.7% vs 0%; P = 0.012).37
The next major advances are likely to come from understanding
how to best use focused‐radiation therapy to modulate a patient's
biological response in combination with innovative radiation delivery
equipment. Use of radiation to prime the immune system and
enhance systemic responses to immunotherapy treatment is an
active area of clinical research.38 Gene‐expression profiling and
molecular imaging may allow for adjustment of radiation dose based
on tumor radiosensitivity39 or response‐based adaptive therapy. Tar-
geted therapies or nanoparticles could exploit tumor‐specific anti-
gens, helping to further localize the effects of radiation, and
increasing the potential to overcome cellular repair and hypoxia limi-
tations. Kwatra et al. demonstrated 2.5‐fold increase in double
stranded DNA breaks when plasmid DNA was bombarded with
60 KeV electrons in the presence of gold nanoparticles.40 Therefore,
equipment development is not stifling innovation in radiation oncol-
ogy, but rather facilitates high‐quality treatments that could lead to
better clinical outcomes.
4 | REBUTTAL
4.A | Leonard Kim, MS, AMusD; Stephanie
Markovina, MD, PhD; Samantha Van Nest, PhD
The litany of equipment developments recited in the “against” open-
ing statement have indeed made significant impacts on our field.
However, these developments: IMRT, SBRT, image‐guided RT (IGRT),
OAR‐sparing devices, all capitalize on the cytotoxic basis of RT: radi-
ating and killing a region of interest. When referring to “the latest in
the innovation chain,” MR‐guided radiotherapy systems, our oppo-
nents themselves essentially refer to this basis as “being further fine‐
tuned,” hardly the language of true innovation. One of the main
points of our opening statement is that equipment development in
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our field is overly focused on improved treatment delivery accuracy,
dominating precious resources of time, and money for diminishing
clinical gains. The way to maximize the benefit of even the most
promising technologies (SBRT, MRI‐guided RT) is not to develop
them further, but to understand how they work. For example, the
biologic effective dose model does not explain why SBRT is less
effective for colorectal cancer (CRC) metastases in the lung com-
pared to NSCLC.41,42 Nor can we determine how best to integrate
SBRT techniques into systemic (metastatic) disease settings without
better biological understanding.
Our esteemed opponents then list developments that many in
the field of radiation oncology are excited about: the combination of
radiation with immunotherapy, gene‐expression profiling and molecu-
lar imaging, and targeted therapies. But these areas depend less on
further equipment development and absolutely require a better
understanding of the biology of radiation and cancer. For example,
one of the studies cited by our opponents (Ref. [38]) was done by
colleagues at the current laboratory of one of our authors (SVN).
Only a moderately increased radiation dose (6–9 Gy per fraction)
was found to be necessary to stimulate immune activity, a dose
already achievable by current clinical instrumentation.43 Rather than
further equipment development, the key problem and limitation for
any clinical implementation of the ideas proposed in the study (as
well as the gene‐expression profiling study cited by our opponents
(Ref. [39]) is biological validation and understanding, without which
further funding approval, clinical trial initiation, and adoption by clini-
cians will be limited.
In the end, the conclusion to which our opponents arrive is our
own exact point. The innovations in our field most likely to make a
significant impact on patient care and outcomes will only be
achieved through better understanding the biology of our therapies
and how radiation treatment may be best applied in a biological con-
text. Investing in these areas — and not equipment development —
is exactly what our field should be doing starting no later than now.
4.B | Subarna Eisaman, MD, PhD; Lakshmi
Santanam, PhD; Julie Sullivan, PhD
We agree with our colleagues' conclusion that radiation oncology
must prioritize overall improvement in quality of life and effective-
ness of therapies and that many gains are to be made by focusing
on answering cancer and radiation biology questions. However, we
want to highlight that equipment development IS part of innova-
tion. Radiation oncology is a blend of biology, physics, and clinical
care, and innovation in the field can only occur when equipment
development occurs in parallel with understanding the biological
basis behind the treatment. Often, equipment development out-
paces our biological understanding as advances in technology have
made engineering a device quicker than biological experimentation.
Advances in molecular techniques such as gene‐expression profiling
have been needed to further insights in general cancer biology.
These in turn have opened new areas of investigation for radiation
biology.44–46
While submillimeter accuracy may not be needed to treat all
tumors, radiation therapy is used to treat a variety of tumor types
that require different levels of accuracy and precision. One example
of the huge clinical impact of submillimeter accuracy is during brain
tumor radiation therapy, especially in children. Dose delivery in such
cases is limited by the tolerance of normal tissues surrounding the
target.47,48 Even with the current precision, nearly all children under-
going brain tumor radiation therapy develop a certain level of cogni-
tive deficits long‐term. The physical basis for the damage to the
nontargeted brain cortex from MV x‐rays or Co‐60 gamma rays is
the spatial distribution of the radiation they produce in the brain.
Specifically, the doses produced to the brain tissue located proximal
and distal to the target are excessive.49 Better accuracy translates to
less normal brain cortex damage. Furthermore, without a reliable and
safe way of accurately delivering radiation in the clinic, even the
most detailed radiobiologic understanding would have limited trans-
lation into real patient care.
As for the concern regarding funding, we are in complete agree-
ment that not enough NIH research dollars are allocated to the
study of basic radiobiology and radiation oncology in general. How-
ever, until this can be changed, any additional funding to help move
our field forward should be not be discounted. There are examples
of equipment development based on evidence where private devel-
opers work in conjunction with the NIH to generate relevant clinical
data. A good example is the emerging data for rectal sparing in pros-
tate cancer. We know risk of rectal toxicity depends on the volume
of the rectum that receives a high‐radiation dose. In a large prospec-
tive series, the percentage of rectum receiving > 70 Gy (V70) corre-
lated with the occurrence of chronic rectal toxicity.50 Based on this
information, in vitro work was supported by NIH grants and cadav-
eric studies funded by an equipment developing company to analyze
risks, benefits, and dosimetric effects of prostate‐rectum separation
using polyethylene‐glycol (PEG)‐based hydrogels.51 Evaluation in a
prospective multicenter randomized controlled trial showed a signifi-
cant reduction in late (3–15 months) rectal toxicity severity.52
Finally, our colleagues make the argument that we may have pla-
teaued on accuracy due to CTV accounting for uncertain margins.
Thus far SBRT ablative doses are delivered without a CTV, therefore,
little to no room for uncertainty. As we head toward immune modula-
tion in combination with radiation therapy and tumor microenviron-
ment modulation with radiation, as predicted by our colleagues, we
will likely need even more accuracy in radiation treatment delivery.
Overall, in order to deliver innovative radiation oncology treat-
ments in the clinic, we will continue to require equipment develop-
ment. Therefore, while it will be essential to answer cancer and
radiation biology questions, equipment development will continue to
be an integral part innovation in radiation oncology.
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